Simon Property Group Inc vs GeneDx Holdings Corp — how do they compare? Simon Property Group Inc trades at $227 (market cap $74.00B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Simon Property Group Inc is far larger — about 41.1× GeneDx Holdings Corp's market cap, and Simon Property Group Inc pays a 3.86% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SPG | WGS | |
|---|---|---|
Market Cap | $74.00B | $1.80B |
Sector | Real Estate | Technology |
52-Week High | $228.70 | $167.51 |
52-Week Low | $160.68 | $34.51 |
Enterprise Value | $102.48B | $1.80B |
Dividend Yield | 3.86% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Trailing returns across standard periods
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →